AKTHELIA SELECTED AS FINALIST FOR THE SCIENCE 2 STARTUP EVENT

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy
Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis
AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES
eliminating the need for prophylactiC antibiotics
reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis

HOME
News
AKTHELIA SELECTED AS FINALIST FOR THE SCIENCE 2 STARTUP EVENT

AKTHELIA SELECTED AS FINALIST FOR THE SCIENCE 2 STARTUP EVENT

February 27, 2018

Akthelia has been selected as a finalist for the Science 2 Startup event which will be held in Cambridge, Massachusetts in April. This will be an all-day symposium with a keynote speaker, poster sessions, and panel discussions to help facilitate better relationships between PIs / TTOs and investors in the biotech community. https://www.science2startup.com/

Febrile neutropenia is a common, life-threatening complication of chemotherapy

Gut barrier Injury and Neutrophil depletion puts patients at risk for bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT BACTERAEMIA BY STRENGTHENING INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events, antimicrobial resistance and microbiome dysbiosis

AKTHELIA SELECTED AS FINALIST FOR THE SCIENCE 2 STARTUP EVENT

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis